Skip to main content
. 2018 May 31;68(2):291–297. doi: 10.1093/cid/ciy452

Table 3.

Chronic Opioid Therapy (COT) Monitoring and Patient Satisfaction With COT Monitoring in a Cohort of People Living with Human Immunodeficiency Virus on COT for Chronic Pain

Characteristic Overall COMM Score ≥9 COMM Score <9 P Value
(n = 165) (n = 71) (n = 94)
COT monitoring
 Ever signed opioid treatment agreement at current clinic 50 (30.3) 28 (39.4) 22 (23.4) .05
 Ever had pain medication stopped due to not following rules of agreement 11 (18.6) 7 (23.3) 4 (13.8) .34
 Ever had urine drug test at current clinic 110 (66.7) 49 (69.0) 61 (64.9) .38
 Ever had pill count at current clinic 20 (12.1) 11 (15.5) 9 (9.6) .25
 Received all 3: treatment agreement, urine drug test, and pill count 8 (4.8) 6 (8.5) 2 (2.1) .08
Patient satisfaction with COT monitoringa
 Opioid treatment agreement, median (25th, 75th percentile) 10 (7, 10) 10 (7, 10) 10 (7, 10) .25
 Urine drug test, median (25th, 75th percentile) 10 (8, 10) 10 (8, 10) 10 (8, 10) .93
 Pill count, median (25th, 75th percentile) 10 (6, 10) 9 (7, 10) 10 (5, 10) .81
Ever received naloxone 17 (10.3) 7 (9.9) 10 (10.6) .87

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: COMM, Current Opioid Misuse Measure; COT, chronic opioid therapy.

aSatisfaction (scale of 1–10: 1 = not satisfied at all, 10 = extremely satisfied) was assessed only among the subgroup who had ever received each respective type of monitoring (ie, for the overall group, opioid treatment agreement, n = 51; urine drug test, n = 110; pill count, n = 20).